Showing 1441-1450 of 1717 results for "".
- Thrombectomy for Acute Stroke Patients with Large Infarcts Associated with Better Outcomes/Lower Mortality vs Medical Care Onlyhttps://practicalneurology.com/news/thrombectomy-for-acute-stroke-patients-with-large-infarcts-associated-with-better-outcomeslower-mortality-vs-medical-care-only/2470469/According to study results published in The New England Journal of Medicine, endovascular thrombectomy plus medical care resulted in better functional outcomes and lower mortality versus medical care alone but led to a higher incidence of intracerebral hemorrhage in patients wi
- Study Identifies Risks Associated with Intravenous Thrombolysis Therapy in Patients with Prior Intracerebral or Subarachnoid Hemorrhagehttps://practicalneurology.com/news/study-identifies-risks-associated-with-intravenous-thrombolysis-therapy-in-patients-with-prior-intracerebral-or-subarachnoid-hemorrhage/2470445/Study results presented at the American Academy of Neurology (AAN) 2024 Annual Meeting demonstrate that patients with a history of intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) who receive intravenous thrombolysis (IVT) for acute ischemic stroke have more than triple the risk of
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Novel Brain Cytoprotection Combination Therapy Associated with Improved Functional Outcomes in People with Acute Ischemic Strokehttps://practicalneurology.com/news/novel-brain-cytoprotection-combination-therapy-associated-with-improved-functional-outcomes-in-people-with-acute-ischemic-stroke/2470408/The use of Sanbexin (edaravone and dexborneol; Simcere, Nanjing, China) sublingual tablets, a formulation combining edaravone and dexborneol, was found to result in statistically significant improvements in functional outcomes for people with acute ischemic stroke (AIS) compared with placebo. The
- Gammagard Liquid Receives FDA Approval to Treat Disability and Impairment Associated with Chronic Inflammatory Demyelinating Polyneuropathyhttps://practicalneurology.com/news/gammagard-liquid-receives-fda-approval-to-treat-disability-and-impairment-associated-with-chronic-inflammatory-demyelinating-polyneuropathy/2470390/Gammagard Liquid (Immune Globulin Infusion [human] 10% solution; Takeda, Cambridge, MA) has been approved by the Food and Drug Administration (FDA) as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating
- Gingipain Inhibitor Cleared by FDA for Investigation as Potential Treatment for P. gingivalis–Associated Alzheimer Diseasehttps://practicalneurology.com/news/gingipain-inhibitor-cleared-by-fda-for-investigation-as-potential-treatment-for-p-gingivalis-associated-alzheimer-disease/2470347/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LHP588 (Lighthouse Pharmaceuticals; San Francisco, CA), a next-generation small-molecule gingipain inhibitor under investigation as a potential treatment for Porphyromonas gingivalis&nda
- Tau-Targeting Investigational Antisense Oligonucleotide Therapy Associated with Favorable Cognition and Clinical Trends in Alzheimer Diseasehttps://practicalneurology.com/news/tau-targeting-investigational-antisense-oligonucleotide-therapy-associated-with-favorable-cognition-and-clinical-trends-in-alzheimer-disease/2470326/Newly reported data related to a study of an investigational antisense oligonucleotide (ASO) therapy BIIB080 (Biogen; Cambridge, MA) showed favorable outcomes for multiple endpoints of cognition and activities of daily living in Alzheimer disease (AD). BIIB080 is designed to target the microtubul
- Emgality Treatment for Migraine Prevention Associated with Migraine Burden Improvements According to TRIUMPH Studyhttps://practicalneurology.com/news/emgality-treatment-for-migraine-prevention-associated-with-migraine-burden-improvements-according-to-triumph-study/2470217/Initial results from an ongoing study demonstrated greater improvements in migraine burden for patients who initiated or switched to Emgality (galcanezumab; Lilly, Indianapolis, IN) treatment for a 3 month period compared w
- Alzheimer's Association Launches ALZ-NET Registry for Study of New Treatments for Alzheimer Disease in Real-World Settinghttps://practicalneurology.com/news/alzheimers-association-launches-alz-net-registry-for-study-of-new-treatments-for-alzheimer-disease-in-real-world-setting/2469988/ALZ-NET is a national network of sites that will be collecting real-world evidence on people being treated with novel treatments approved by the Food and Drug Administration for the treatment of Alzheimer disease. This clinical registry is a model that has been used in other disease states, inclu
- Lamotrigine, Levetiracetam and Other Antiseizure Medications During Pregnancy Not Associated With Developmental Delays at Age 3 Yearshttps://practicalneurology.com/news/lamotrigine-levetiracetam-and-other-antiseizure-medications-during-pregnancy-not-associated-with-developmental-delays-at-age-3-years/2469520/According to a preliminary study, children born to women taking certain antiseizure medications (ASMs) for epilepsy during pregnancy had no higher risk of developmental delays at age 3 years when compared with children of women without epilepsy. The study involved 275 individuals